ACER — Acer Therapeutics Balance Sheet
0.000.00%
- $19.68m
- $50.19m
Annual balance sheet for Acer Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 41.7 | 12.1 | 5.76 | 12.7 | 2.33 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | 5 | 0 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 42.7 | 12.9 | 6.44 | 28.1 | 3.52 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.131 | 0.794 | 0.53 | 0.114 | 0.415 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 50.7 | 21.5 | 14.6 | 36.3 | 11.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.58 | 2.77 | 6.15 | 29.1 | 19 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.58 | 3.1 | 6.39 | 38 | 28.4 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 45.1 | 18.4 | 8.22 | -1.72 | -16.8 |
| Total Liabilities & Shareholders' Equity | 50.7 | 21.5 | 14.6 | 36.3 | 11.6 |
| Total Common Shares Outstanding |